IMMUNOCORE HLDGS ADS/1 (6YG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) has a cash flow conversion efficiency ratio of 0.038x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€15.93 Million ≈ $18.62 Million USD) by net assets (€419.80 Million ≈ $490.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 6YG company net worth for the company's overall valuation and market capitalisation.
IMMUNOCORE HLDGS ADS/1 - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's cash flow conversion efficiency has evolved over time, based on yearly financial data.
IMMUNOCORE HLDGS ADS/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IMMUNOCORE HLDGS ADS/1 ranked by their cash flow conversion efficiency. Explore how high is IMMUNOCORE HLDGS ADS/1's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LIBERTY LAT.AMER.C DL-01
F:1LLC
|
0.434x |
|
Svitzer Group A/S
CO:SVITZR
|
N/A |
|
Sinofibers Technology Co Ltd
SHE:300777
|
-0.022x |
|
Tibet Tianlu Co Ltd
SHG:600326
|
0.030x |
|
Hong Leong Industries Bhd
KLSE:3301
|
0.056x |
|
Shandong Yisheng Livestock & Poultry Breeding Co Ltd
SHE:002458
|
0.021x |
|
One Software Technologies Ltd
TA:ONE
|
0.082x |
|
HHC Changzhou Corp.
SHE:301061
|
N/A |
Annual Cash Flow Conversion Efficiency for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below shows the annual cash flow conversion efficiency of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025. View IMMUNOCORE HLDGS ADS/1 (6YG) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €381.03 Million ≈ $445.47 Million |
€-10.71 Million ≈ $-12.52 Million |
-0.028x | -138.91% |
| 2024-12-31 | €360.72 Million ≈ $421.71 Million |
€26.06 Million ≈ $30.47 Million |
0.072x | +806.40% |
| 2023-12-31 | €368.84 Million ≈ $431.22 Million |
€2.94 Million ≈ $3.44 Million |
0.008x | +105.49% |
| 2022-12-31 | €338.90 Million ≈ $396.21 Million |
€-49.21 Million ≈ $-57.53 Million |
-0.145x | -- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more